High TNFRSF1B (TNFR2) expression in tumor‐infiltrating Tregs; TNFR2 inhibition reduces immune‐related adverse events while maintaining ICB efficacy (TIL中Treg的TNFRSF1B). The gene discussed is TNFRSF1B; the disease is neoplasm.